9% to 90.3%. Collectively, 57.3% of all subjects were completely asymptomatic at the end of treatment. Key Word(s): 1. GERD; 2. Reflux; 3. F Test; 4. PPI;   Pre-Treatment* Post-Treatment* Patients with a Positive Response to Therapy Patienst with No Response to Therapy Question Yes No Yes No * Difference between pre- and post-treatment responses, p value < 0.001, McNemar's test. 1161/1348 (86.1) 187/1348 (13.9) Nakakaramdam ka ba ng sakit, hapdi o init sa sikmura na

gumuguhit paakyat selleck kinase inhibitor hanggang dibdib? (Nakakaramdam ka ba ng “Oheartburn?”) 1232/1381 (89.2) 149/1381 (10.8) 1128/1287 (87.6) 159/1287 (12.4) 1099/1285 (85.5) 186/1285 (14.5) 943/1151 (81.9) 208/1151 (18.1) 1049/1215 (86.3) 166/1215 (13.7) 793/952 (83.2) 159/952 (16.7) 1137/1259 (90.3) 122/1259 (9.7) 1139/1279 (89.1) 140/1279 (10.9) 1013/1213 (83.5) 200/1213 (16.5) 907/1094 (82.9) 187/1094 (17.1) 1037/1236 (83.9) 199/1236 (16.1) Presenting Selleck Temozolomide Author: UDAYCHAND GHOSHAL Additional Authors: DEEPAKSHI SRIVASTAVA, UJJALA GHOSHAL, ASHA MISRA Corresponding

Author: UDAYCHAND GHOSHAL Affiliations: SGPGIMS, Lucknow Objective: Antibiotic is effective in relieving symptoms in half of unselected patients with irritable bowel syndrome (IBS), but data on its efficacy in patients selected according to small intestinal bacterial overgrowth (SIBO) tests are lacking. Methods: 80 patients with IBS (Rome III) were evaluated for SIBO (upper gut aspirate culture and GHBT). Patients were allocated to receive norfloxacin or placebo for 10 days based on presence (> 105 CFU/mL) or absence of SIBO (stratified randomization, computer generated table). Symptom-score and Rome III criteria were compared before and one month after treatment and eradication of SIBO documented using culture and/or GHBT. Results: Of 15/80 (19%) 2-hydroxyphytanoyl-CoA lyase patients with SIBO on upper gut aspirate culture (4 of them by GHBT as

well), 8 were randomized to norfloxacin and 7 to placebo; of other 65 patients, 32 received norfloxacin and 33 placebo. Rome III criteria more often became negative in patients with SIBO (> 105 CFU/ml) than those without colonization (<103 CFU/ml) (7/8 [87.5%] vs. 3/21 [14.3%], p = 0.0005) and there was a trend among those with moderate colonization (> 103 to < 105 CFU/ml) (5/11 [45.5%] vs. 3/21 [14.3%], p = 0.08) but did not become negative in anyone with placebo. Symptom-score improved with norfloxacin (SIBO group: 6.5 (2–13) vs. 2 (0–10), p = 0.01; moderate colonization group: 10 (2–16) vs. 5 (1–12), p = 0.005; non-colonized group: 8 (3–16) vs. 5 (0–12), p < 0.001) than with placebo (10 [5–13] vs. 11 [2–14], p = ns; 6 [4–12] vs. 6 [4–12], p = ns; 9 [1–17] vs. 9 [2–18], p = ns, respectively). On repeat testing, all 4/8 consenting patients with norfloxacin became negative (2 by culture and GHBT and 2 by GHBT alone) but none of the 7 with placebo.